BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)
Clinical trials for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE) explained in plain language.
Never miss a new study
Get alerted when new BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE) trials appear
Sign up with your email to follow new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer drug trial pulled before starting
Disease control TerminatedThis was a planned Phase 3 study testing a drug called NDV-01 (a slow-release combination of two chemotherapy drugs) for people with a type of bladder cancer that did not respond to standard BCG treatment. The goal was to see if the drug could make the cancer disappear, but the s…
Matched conditions: BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 09:06 UTC
-
Bladder cancer drug trial halted before it began
Disease control TerminatedThis study was designed to test if a new drug called NDV-01 could keep bladder cancer from returning after surgery. It was for people with intermediate-risk non-muscle invasive bladder cancer. However, the trial was withdrawn before enrolling any participants, so no results are a…
Matched conditions: BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC